Role of Melatonin in Cancer Treatment

Melatonin has revealed itself to be a pleiotropic and multitasking molecule. The mechanisms that control its synthesis and the biological clock processes that modulate the circadian production of melatonin in the pineal gland have been well-characterized. A feature that characterizes melatonin is th...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 32; no. 7; pp. 2747 - 2753
Main Authors CUTANDO, Antonio, LOPEZ-VALVERDE, Antonio, ARIAS-SANTIAGO, Salvador, DE VICENTE, Joaquin, DE DIEGO, Rafael Gomez
Format Journal Article
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.07.2012
Subjects
Age Factors
Biological and medical sciences
Cell Transformation, Neoplastic - metabolism
Clinical Trials as Topic
Humans
Medical sciences
Melatonin - metabolism
Melatonin - pharmacology
Melatonin - therapeutic use
Neoplasms - drug therapy
Neoplasms - metabolism
Tumors
Melatonin
Cancerology
Treatment
immune mechanisms
review
Malignant tumor
melatonin receptors
Mechanism
Bibliographic review
Pineal hormone
Cancer
Biological receptor
Online AccessGet full text

Cover

More Information
Summary:Melatonin has revealed itself to be a pleiotropic and multitasking molecule. The mechanisms that control its synthesis and the biological clock processes that modulate the circadian production of melatonin in the pineal gland have been well-characterized. A feature that characterizes melatonin is the variety of mechanisms it employs to modulate the physiology and molecular biology of cells. Research has implicated the pineal gland and melatonin in the processes of both aging and age-related diseases. The decline in the production of melatonin with age is thought to contribute to immunosenescence and potential development of neoplastic diseases. Melatonin has been shown to inhibit growth of different tumors under both in vitro and in vivo conditions. There is evidence that the administration of melatonin alone or in combination with interleukin-2 in conjunction with chemoradiotherapy and/or supportive care in cancer patients with advanced solid tumors, has been associated with improved outcomes of tumor regression and survival. Moreover, chemotherapy has been shown to be better tolerated in patients treated with melatonin.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0250-7005
1791-7530